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ABSTRACT

Glutaraldehyde crosslinked bovine pericardium has been used for fabrication of
bioprosthetic heart valves as well as cardiac patches for soft tissue repair. However,
calcification and limited mechanical stability result in shortened life for the prostheses.
Previous research has shown that glutaraldehyde crosslinking does not stabilize
glycosaminoglycans (GAGs) and that GAGs are lost from porcine bioprosthetic heart
valves[1]. Bovine pericardial tissue is composed of an amorphous network of collagen
and elastin fibers, proteoglycans, and GAGs. The GAGs of bovine pericardium include
dermatan sulfate, chondroitin sulfate, and hyaluronan [2].
It is hypothesized that Glut does not stabilize GAGs in pericardium and loss of
GAGs may play a role in the degenerative failure of pericardial valves. Also stabilizing
GAGs in the extracellular matrix of the pericardial valves may improve their function and
extend their life. The objectives of this study were to 1) characterize the structure of
bovine pericardium and determine the contribution of GAGs to the structure and
mechanical behavior of the tissue; 2) determine the effectivness of glutaraldehyde
fixation in the retention of GAGs; 3) determine the effectiveness of GAG stabilizing
fixation of Neomycin enhanced carbodiimide crosslinking chemistry; 4) determine the
stability of GAGs in vivo and correlation with calcification.
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CHAPTER ONE
INTRODUCTION

1.1 Valvular Heart Disease
Almost 79.4 million people in the United States have one or more cardiovascular
disease, which is almost one in every three Americans. For the year 2007 it was expected
to cost $431.8 billion dollars for medical treatment of cardiovascular disease in the
United States alone [3]. Cardiovascular disease includes high blood pressure, coronary
heart disease, stroke, and congestive heart failure. Valvular heart disease is one such
disease that can lead to heart failure and death. In 2002, nearly 99,000 inpatient valve
procedures were performed in the United States [3].
The heart and cardiovascular system provide oxygen and nutrient transport to the
body as well as removal of metabolic waste. The heart possesses four valves to control
the unidirectional flow of blood to the heart and lungs. Two semi-lunar valves are
located at the outlets of the left and right ventricle, the Aortic and Pulmonary valves
respectively. As the ventricles contract, pressure increases, and the valve leaflets are
passively pushed upward away from the center of the lumen allowing blood to be
expelled from the ventricle during ventricular systole. During ventricular diastole the
cusps passively fall back into the lumen, supporting the blood flowing in from the atria.
Also two atrio-ventricular valves, the Mitral and Tricuspid, are positioned at the inlets of
the left and right ventricles respectively. These valves control of blood flow into the
ventricles from the atria, and are more complex than the semi-lunar valves. The atrio-
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ventricular valves have chordae tendineae inserted into the free edge of the cusp and are
connected to the papillary muscles and myocardium along the ventricle wall. As the
ventricle contracts, the papillary muscles contract pulling the chordae tendineae to pull
the valve leaflets down and together to prevent the back flow of blood from the ventricle
and allowing the atria to fill [4].
Historically, rheumatic heart disease was the most common cause of valvular
disease. After 1950 penicillin was prescribed to treat streptococcal infection, preventing
rheumatic fever, and decreasing the occurrence of mitral valve stenosis [5]. The majority
of valve procedures performed today continue to be the mitral and aortic valves. Theses
procedures address valvular stenosis and insufficiency. Stenosis is defined by obstruction
of blood flow, and valve insufficiency describes both regurgitation (back flow) and
incompetence[6].
Mitral stenosis is still predominately caused by rheumatic fever, but can also be
due to congenital conditions or calcification. Since the use of antibiotics mitral valve
insufficiency has become a more prominent problem[6, 7]. Mitral valve regurgitation is
due

to

myxomatus

degeneration

(mitral

valve

prolapse)

or

mucopolysaccarides in the spongiosa, increasing cuspal thickness.

deposition

of

Dilation and

calcification may also occur, further altering the structure of the valve. The increase in
cuspal thickness inhibits the valve from functioning normally, as the cusps can not align
to close the valve and support the blood filing the atria.

The development of mitral

valve prolapse is associated with acquired disorders leading to cuspal degeneration, as
well as genetic disorders of connective tissue such as Marfan syndrome[4]. Only 11% of
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patients with mitral valve prolapse require surgical intervention. Undiagnosed, however,
asymptomatic patients have a 33% risk of heat failure and other adverse affects [6].
Aortic stenosis is the most prevalent valvular condition. Blockage of blood flow
through the aorta can be a result of a congenital condition, or acquired by rheumatic heart
disease and calcification[6]. Calcification of degenerative valves is frequently the cuase
for valve replacements in patients over 70 years of age. With calcific aortic stenosis the
aortic valve area is dramatically reduced, limiting the blood flow from the left ventricle
as well as increasing the pressure gradient. To compensate for the changes the left
ventricle becomes hypertrophic. Other possible causes of aortic stenosis include fungal
endocarditis and atherosclerosis in patients with extremely elevated cholesterol levels [4].
Aortic insufficiency, less prevalent than aortic stenosis, is present as acute and
chronic aortic regurgitation.

Acute regurgitation is typically the result of infective

endocarditits, dissection of the aorta, systemic hypertension, or trauma. Hypertension
can be controlled by pharmacotherapy, reducing the degree of regurgitation, only if
permanent damage as not occurred. Valve replacement or repair is needed when there
are indications for congestive heart failure.

Chronic aortic regurgitation is most

commonly caused by aortic root dilation, followed by congenital bicuspid valve,
rheumatic fever, other congenital conditions affecting the connective tissue, and syphilis.
Valve replacement depends on the severity of regurgitation. Vasodilators may be given
prior to surgical replacement or alone in less severe cases to reduce the peripheral artery
resistance and therefore degree of regurgitation volume[4].
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1.2 The Native Heart Valve
Healthy, normal valves of the heart allow flow of blood in one direction without
obstruction, allowing regurgitation, thromboembolism, or extreme stress to the leaflets.
Proper function of the heart requires all components of the valve to be structurally intact
and work in unison[6]. The semi-lunar valves (aortic and pulmonary) each consist of
three fibrous cusps, attached at the aortic or pulmonary root, with equal space between
the attachments of adjacent cusps called commisures. The ventricular surface of the free
edge of each cusp contains a small nodule, which meet at the center when the valve is
closed to provide resistance to mechanical load due to the pressure difference across the
valve. The cusps also provide support under mechanical load by stretching and the
interaction of the extracellular matrix of the individual layers of the cusp [4, 6]

The

aortic heart valve leaflet structure, as shown in Figure 1, is composed of three layers, the
fibrous layers of the fibrosa and ventricularis are separated by the spongiosa.
The ventrcularis, the layer facing the ventricular cavity, is composed of collagen
with elastin fibers arranged in the radial direction through the cusp. The abundance of
elastin in the ventricularis provides the elasticity needed for the cusp to contract against
the wall when the valve is open reducing the surface area. Elastin also provides the
tension needed to close the valve, stretching the cusp to increase the coaptation area.
Circumferentially aligned collagen fibers of the fibrosa run parallel to the free edge of the
cusp, provides strength as well as stiffness to each cusp to maintain the curvature and
prevent the back flow of blood.

The central layer of the cusp, the spongiosa, is

comprised of loosely arranged collagen fibers and glycosaminoglycans. The spongiosa,
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while not a source of strength in the cusp, adjusts to changes in orientation of the cusp
throughout the cardiac cycle. The interactions of the network of fibers in the cusp serve
to transmit the load produced by the ventricular pressure to the fibrous annulus and vessel
wall. Maintenance of this extracellular matrix is accomplished by the valvular interstitial
cells. Continuous synthesis, degradation, and re-organization of the ECM by matrix
degrading enzymes such as matrix metalloproteinases ensure the durability and
functionality of the valve [6].

Figure 1: Internal Structure of Aortic Valve Leaflet [8]

1.2.1 Collagen
The most abundant component of the extracellulalr matrix is collagen which is
present in many tissues such as tendon and skin.

Collagen is the tensile resistant

component of the ECM and self aligns in the direction of tension [9]. It is present in the
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heart valve leaflet as collagen types I, III, and IV. Collagen I is the primary element of
the fibrosa as interweaving, parallel fibers. It also exists in smaller amounts in the
ventricularis and spongiosa. Collagen III is located in modest amounts in all three layers
as intertwined, wavy fibers. Collagen IV is also found in smaller amounts through out
the leaflet [10].

1.2.2 Elastin
Elastin fibers interwoven with collagen are prominent in the inflow layer of the
ventricularis.

Fibrosa and Spongiosa layers contain smaller amounts of intertwined

elastin fibers[10]. The radially aligned elastin fibers place tension on the collagen of the
ventricularis, and act as a spring returning the collagen to their original position after
loading has been removed as indicated below in Figure 2 [8].

Figure 2: Collagen-Elastin Matrix [11]
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1.2.3 Glycosaminoglycans
Glycosaminoglycans (GAGs) are linear polysaccharides of repeating disaccharide
units. One monosaccharide is an amino sugar, and the other is typically uronic acid.
GAGs are negatively charged and hydrophilic making them able to absorb water.

The

GAG chains are covalently attached to a serine residue on a core protein, resulting in
molecules called proteoglycans [12]. Proteoglycans, and their negatively charged GAG
side chains, are present in all three layers of the heart valve leaflet at varying levels
depending on the proteoglycan. However, they are more concentrated in the spongiosa
layer. The proteoglycan distribution is dependent on the type of GAG side chain as well
as the type of collagen present [10]. There are three types of proteoglycans of different
lengths in native heart valve tissue. The smallest proteoglycan decorin is aligned along
collagen and has chondroitin and dermatan sulfate GAG side chains. Perlecan is found
along the cell surface and elastin fibers and contains heparin sulfate GAG side chains.
Versican, the largest proteoglycan present, also contains chondroitin and dermatan sulfate
GAG side chains. Hyaluronate is a GAG that is not bound to a protein core [13].
The mechanical role of glycosaminoglycans in heart valve tissue is still being
established.

Vyavahare, et al. have shown that fatigue of collagen films and

glutaraldehyde crosslinked porcine aortic bioprostheses results in loss of GAGs as well as
structural changes in collagen. Mechanical testing following fatigue demonstrated a
reduction in flexural rigidity indicating a loss of the natural stiffness and susceptibility to
failure [14]. Removal of GAGs from cusps results in decreased cusp thickness, water
content, as well as decreased ability to re-hydrate [1]. Fatigue is not the only mechanism
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resulting in GAG loss. Naturally there is a high turn-over rate of GAG synthesis[15].
There are also large quantities of GAG degrading enzymes in natural cusp tissue [16].

Figure 3: Glycosaminoglycan structure

1.3 Heart Valve Replacements
Diseased heart valves require either surgical repair or replacement. The ideal
replacement would function similar to the native valve, allowing uninhibited forward
flow when open, but preventing backward flow (regurgitation) when closed.

The

replacement valve would also not cause turbulent blood flow, but limit hemolysis and the
coagulation cascade.

The prosthetic valve should be biocompatible, having non-

thrombogenic blood contacting surfaces. Ease of implantation with low morbidity rates
is essential.

Durability for the patient lifetime is critical to avoid repeat operation

because of device failure. Finally, the ideal prosthetic valve would not affect the daily
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activity of the patient. The quality of life for the patient would be improved if no
anticoagulation therapy was necessary, no noticeable sounds were produced by the valve,
and if there was a low risk of endocarditis[17-19].

Table 1: Characteristics of the ideal heart valve replacement[18, 19]
Non-obstructive and Natural Hemodynamics
Non-thrombogenic
Infection resistant
Chemically inert and non-hemolytic
Extended durability
Easily implanted
Appropriate healing at prosthesis interface
Patient comfort and quality of life

Current replacements are limited to mechanical or tissue valves.

Both have

specific advantages and disadvantages and depending on the patient’s age, sex, and health
one type may be better suited than the other. There are concerns of durability for both
young and old patients, as well as the patients’ ability to take anti-coagulation medication
[20]. There are multiple mechanical and bioprosthetic valves currently approved by the
FDA for use as shown in Tables 2 and 3.
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1.3.1 Mechanical Heart Valve Replacements
Mechanical heart valves were introduced in the 1950s with the design of the ball
in cage valve. The most notable being the Starr-Edwards ball valve. The initial design
has remained almost unchanged except for iterations in the design for example the Lucite
cage was replaced by a satellite metal cage with a silicone-elastomer ball. The first ball
in cage valve implantation occurred in the 1960’s, and now with over 250,000 StarrEdwards valves implanted worldwide as of 2003 [21]. Advantages of the caged ball
design include that no audible sound is produced by the valve opening and closing.
Disadvantages however, are that turbulent blood flow is induced by the valve and
therefore necessitates anticoagulation therapy. The high profile of the cage also causes
complications as it extends into the ventricle or aorta depending on implant site[17].
With the advent of new designs including the tilting disk and bileaflet, use of the StarrEdwards valve has been discontinued in the United States, but it is continued to be used
in less developed countries due to the reasonable cost [21].

Table 2: FDA Approved Mechanical Heart Valves
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Figure 4: Edwards Life Sciences Mechanical Valves 1) Bileaflet Valve, 2) Tilting disk
valve, and 3) Ball and cage valve (www.lifeisnow.com)

In the late 1960’s mechanical valve design experienced advancement with the use
of pyrolytic carbon and the concept of the tilting disk to replace the ball-in-cage valve.
The Bjork-Shiley tilting disk valve was the first of its kind but now three tilting disk
valves have been approved by the FDA for use in the United States [21]. The disk of
each consists of graphite which is coated with pyrolitic carbon. The disk is housed in a
circular ring with a sewing cuff as shown in Figure 4.
The latest and most commonly implanted mechanical valve is the bileaflet valve.
Initial prototypes were developed in the late 1960’s. The bileaflet valves currently used
include the St. Jude Medical and CarboMedics valves which where first implanted in
1977 and 1986 respectively [21]. These offer a wider opening angle than the tilting disk
design, but still have the common complication of thrombosis necessitating
anticoagulation therapy[17].
The ultimate choice for heart valve prosthesis depends on the patient conditions
and surgeon’s preference. Although mechanical valves have better durability, there is
still a risk for thrombo-embolism and life long anticoagulation treatment is required. For
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children with bioprosthetic heart valves the chances for calcification are much greater, as
well as either valve will not grow with the patient making repeat surgery necessary[20].

1.3.2 Bioprosthetic Heart Valve Replacements
Mechanical

valves

require

life-long anticoagulation,

and

have

altered

hemodynamics, while tissue valves have hemodynamics similar to the native valve and
typically require anticoagulation only temporarily after surgery. In the 1960’s allografts
began the use of tissue valves for replacement of diseased tissue. Carpentier, in 1972
developed the technique for using chemically treated tissue for valve replacement,
establishing the bioprosthetic valve.

There are currently three approved types of

bioprosthetic valves: bovine pericardial valves, porcine aortic valves (with and without
stents), and allografts. FDA approved bioprosthetic valves are listed in Table 3 [17].

Table 3: FDA Approved Bio-prosthetic Heart Valves
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The benefits of bioprosthetic grafts include decreased thrombogenicity, no sound
produced by the valve movement, and only short-term anti-coagulation is required.
Despite these advantages tissue valves are not ideal because they do not last over 15 – 20
years.

Failure occurs uniformly across bioprosthetic valve types due to structural

deterioration, leaflet wear, and calcification[17].

Figure 5: Edwards Life Sciences Bioprosthetic Valves, 1) Bovine pericardial stented
valve, 2) porcine stented valve, and 3) porcine stentless valve (www.lifeisnow.com)

First generation porcine bioprosthetic valves include the Carpentier-Edwards and
Hancock (Medtronic) valves, which were available in the 1970’s. Fresh porcine aortic
valves were chemically treated in glutaraldehyde at high pressure to maintain valve
coaptation and were then mounted on stents. The second generation porcine xenografts
(Carpentier-Edwards duraflex and Hancock II) improved long-term durability by treating
tissue with anto-mineralization agent, and fixing at lower pressures to not distort the
collagen fiber architecture[17, 20, 22-25].
Bovine pericardial bioprosthetics first prototype was the Ionescu-Shiley valve in
1970, but due to accelerated deterioration implantation was stopped.

Carpentier

improved the valve by mounting the tissue to a flexible stent, and modifying the
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mounting procedure to reduce shear stress and tears. From this development came the
Carpentier-Edwards Perimount that is currently available[17].
Tissue valves can be either allograft or bioprosthetic which are constructed from
porcine valves or bovine pericardium. While having improved hemodynamics, these
valves fail within 15 years because of calcification and loss of mechanical durability[26].
The devices are sufficient for elderly patients with a shorter life expectancy; however, the
current devices are insufficient for pediatric patients or patients whose valves must last
much longer than 15 years[17].

1.4 Pericardial Tissue
1.4.1 Components and Structure
Bovine pericardium is used as a biomaterial in numerous prostheses such as
cardiac patches, replacement chordae tendinae in mitral valves, reconstruction of
ligaments in the knee and hand, and most prominently as leaflets for heart valves [27].
Pericardial tissue is the sac surrounding the heart which provides a natural barrier to
infection for the heart and prevents adhesions to the surrounding tissue. The pericardium
also serves mechanical roles by preventing over dilation of he heart, maintaining the
correct anatomical position of the heart, and regulating the pressure to volume ratio in the
left ventricle during diastole[27-29]. The structure of the tissue determines its behavior
under loading in both conditions physiologic to the pericardium and as a prosthetic
device. The two layer serous membrane is divided by the pericardial cavity which
contains a lubricating fluid. The outer layer, the parietal pericardium, is easily removed
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from the heart and as such is the portion used in bioprostheses. The parietal pericardium
is attached to the sternum by sterno-pericardial ligaments and the diaphragm by loose
fibrous tissue. Removal of fatty cells and connective tissue leaves the fibrosa, the portion
which provides the mechanical properties to the tissue[27].

Figure 6: Structure of Pericardial Tissue

The fibrosa is composed of multiple layers of collagen bundles which vary in
direction with elastin interwoven through the layers. It is interesting to note that in
human fetus pericardial tissue the collagen fibers are straight and delicate; as elastin
develops the collagen becomes wavy. With age, as the tissue becomes less organized, the
collagen fibers lose their waviness [30]. This as well as other studies indicate the
dynamic nature of pericardial tissue, in that the structure is modified to compensate for
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mechanical loading in the normal physiologic conditions.

Loading as well as

environmental and other factors result in structural variation between animals as well as
within the sac [27]. Pericardial tissue is dynamic in that its structure is modified to
compensate for mechanical loading in its normal physiologic conditions. Therefore there
are environmental and other factors that affect the tissue structure resulting in variation
between animals, as well as with in the sac [27, 31].
Variations within the sac and amongst animals include differences in fiber
alignment, extensibility, and thickness. These and other factors have been examined and
categorized noting preferred areas of selection [32-37]. With some variation, the tissue
over the left ventricle has been suggested by many studies to be the most optimum as this
area also experiences the greatest mechanical stress [33, 34].

However individual

analysis of the tissue structure would provide more uniform and accurate selection of
tissue by alignment [33, 36].

1.4.2 GAGs in Pericardial Tissue
The pericardial matrix is 95% laminated collagen fibers (types I and III)
interwoven with elastin (4%) and small proteoglycans with glycosaminoglycans
(~1%).[38, 39]. Proteoglycan containing dermatan sulfate which is 4-sulfated, is the
most abundant in the pericardial tissue[40, 41]. Other GAG disaccharides found in the
tissue include hyaluronic acid, and 0-sulfated glycosaminoglycans [2]. The number
sulfated corresponds to the position on the carbon ring of the sulfate group. The repeating
disaccharides are covalently bound to a core protein (except hyaluronan). The sulfate and
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carboxyl groups of GAGs are negatively charged rendering the tissue hydrophilic. This
hydrophilicity may plan an important role in the water content and subsequent
viscoelasticity of the tissue [2].

Viscous fluids always experience movement as a

response to shear forces. Viscoelastic solids typically exhibit signs of stress relaxation
and creep with a distinct hysteresis loop. Hysteresis is present when the response on the
stress strain curve varies between loading and unloading, indicating the ability to
dissipate mechanical energy[27].

Figure 7: GAG Disaccharides: (A) hyaluronic acid, (B) dermatan sulfate, (C) chondroitin
sulfate, (D) heparan sulfate, and (E) keratan sulfate.

The mechanical role of GAGs in the pericardium has been investigated by
Mavrilas et al. After enzyme removal of GAGs from glut fixed pericardium, the tissue
was tested under dynamic tensile testing. However, the difference in hysteresis was not
significant after removal of GAGs. However this could be due to incomplete removal of
GAGs as only 17% of the total GAGs were removed [2].
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1.4.3 Mechanical Properties of Bovine Pericardium
With regard to mechanical durability, further evaluation of pericardium as a
biomaterial has been investigated to determine the safety of a potential chemical
treatment or origin of the tissue. Many testing methods have been utilized to evaluate
bovine pericardial tissue properties which include uniaxial tensile testing of ultimate
strength [42], high strain rate testing at both small and large deformations [43], shear
testing [44], compressive buckling[45], flexural mechanical response by three-point
bending [46], and dynamic cyclical uniaxial loading for extended duration [47]. The
multidirectional fibers are the cause of the anisotropic property of the tissue. As a result
mechanical loading in one direction will have varying outcomes depending on the
alignment and orientation of the test selection[48-50].
The tearing strength of pericardium under uniaxial loading indicates that the
tissue damage occurs with or without tears by de-lamination of the layers, shear, and
rupture of the tissue [42].

High strain rate testing provides better analysis of the

viscoelastic properties of fixed pericardium with evaluation at both small and large
deformations [43]. Shear testing indicates that glut fixed bovine pericardium has a high
resistance to shear possibly due to the increased stiffness and disruption of collagen fibers
caused by glut fixation [44]. Compressive buckling of pericardium showed that greater
compressive forces are required to cause collapse as compared to porcine leaflets,
because of the dense layering of collagen in pericardium [45]. Three-point bending
found that native and glut fixed bovine pericardium were more stiff when flexed in the
direction perpendicular to the preferred fiber orientation, which would suggest that the
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flexural properties of pericardium are due mainly to the cross links between fibers and
not the actual collagen fibers [46]. Cyclical loading provides an indication of the tissues’
response to fatigue and suggest the importance of the original collagen orientation [47].

1.5 Bioprosthetic Valve Failure
1.5.1 Non-Calcific Deterioration
The majority of bioprosthetic valves fail either because of structural deterioration,
calcific deterioration, or both.

Structural deterioration of prosthetic valves leads to

stenosis and regurgitation which requires undesirable immediate surgical treatment and
repeat procedures. Non-calcific deterioration in many cases is a result of valve design or
material selection. Results also indicate that damage to collagen fibers and tearing of
cusps can occur independently of calcification [51, 52]. Early pericardial bioprostheses
experienced failure after punctures and tears in the tissue near points of attachment on the
stent [53, 54]. Abrasion of the tissue on struts of the stent or Dacron coating cause
regions of damaged collagen bundles [55]. This abrasion and shearing of tissue also
results in tearing of the valve cusp at contact with suture which produces points of
concentrated stress [27, 56]. Modifications to the design of pericardial valves improved
the resistance to tears at the commisures with the Carpentier-Edwards stented bovine
pericardial valve which secures the cusp from inside the frame of the stent [57]. Other
valve design changes include lower profile stents that are more flexible [18]. Although
design alterations can improve resistance to tearing, failure due to deterioration has not
been eliminated.
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Figure 8: Non-calcific failure of bovine pericardial bioprosthetic valve[57]

The presence of tears and structural degeneration is also due to material wear.
The dynamic loading of cusps results in damage to the extracellular matrix [55]. The
cyclical loading of valve cusps, during opening and closing, results in buckling and
rupture of collagen fibers [58].

Although porcine bioprostheses tend to be more

susceptible to buckling as pericardial tissue is more dense and lacks the loose network of
the spongiosa found in the aortic cusp, which collapses due to compressive forces [45].
Mechanical loading also accelerates the enzyme degradation of bovine pericardial tissue
resulting in damage to the matrix from two sources [59]. This furthers the idea that one
single act does not typically cause the failure of a valve. Degeneration and ultimate
failure of prosthetic valve tissue is a multifaceted occurrence, with many factors affecting
the durability and lifetime of a specific valve.
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Shearing of the layers of prosthetic valves may also play a role in tears of cusps
and valve failure [27]. The viscoelasticity of the tissue affects the mechanical properties
of the tissue and its resistance to shear. Recently GAGs have been studied in relation to
their role in valve mechanics and failure. Examination of failed implanted porcine aortic
valves revealed a loss of GAGs [60]. Fatigue of glut fixed porcine valves also showed a
loss of GAGs and damage to collagen fibers [61]. The removal of GAGs from porcine
tissue has permanent affects on the mechanical properties of the tissue [62].

1.5.2 Calcification
Calcific structural deterioration of bioprosthetic valves is slightly more prevalent
than non-calcific deterioration[57].

The progression of calcification results in

compromised tissue structure. The accumulation of calcium typically occurs because
non-viable cells of the prosthetic valve are not able to sustain the pre-existing lower
concentration of calcium in the cell. Calcium binds to the phospholipids membrane of
organelles creating mineralization. Extracellular matrix components of collagen and
elastin as well as debris can provide additionally locations for calcium nucleation [57].
The presence of glutaraldehyde in the tissue makes the tissue more susceptible to mineral
deposition [63, 64]. It is also important to note that calcification of elastin occurs
whether it is crosslinked or not, while calcification of collagen is dependent on the
presence of aldehyde cross linking [61, 65].
Mineralization of the tissue begins with small deposits and progresses to where
tissue thickness can double after 112 days of implantation [66]. As the deposits grow,
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nodules can pierce through the tissue surface inducing further structural damage [66].
The effects of calcification and structural deterioration may be a cooperative progression.
The mechanical stress caused by loading and unloading of cusps has resulted din
increased calcification [67, 68]. Calcium deposits have also been found in areas of high
movement and stress such as the commissural region [64, 66]. The disruption of the
tissue matrix can expose and produce new sites for calcium deposition, while the damage
from calcification results in increased structural disruption [18]

Figure 9: Calcified Bovine Pericardial Bioprosthetic Heart Valve [26]

Pathological mineralization of the prosthetic tissue resembles that of the
physiological calcification of bone. Deposition of calcium phosphate, closely related to
hydroxyapatite, at the cell membrane as well as calcification of the extracellular matrix
occurs [18, 66]. Key molecules in bone formation include osteopontin, osteonectin, and
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osteocalcin. Osteopotin, an acidic calcium binding phosphoprotein [69, 70], has been
found in calcificed bioprosthetic valves as well as calcified native heart valves [71-73].
Studies of cartilage have initiated the theory that GAGs and proteoglycans may
play a role preventing tissue mineralization by binding calcium and preventing the
nucleation of hydroxyapatite [74]. One hypothesis is that the loss of GAGs may result in
voids or areas available for calcium nucleation [75].

In bioprosthetic tissue, removal of

GAGs resulted in increased calcification of bovine pericardium [76].

Preservation,

stabilization and addition of GAGs has also proved to inhibit calcification [77-79].
However, other studies have indicated no prevention of mineralization with alternate
stabilization of GAGs [80, 81].

Thus the role of GAGs in bioprosthetic valve

calcification remains unknown.

1.6 Glutaraldehyde Fixation
Glutaraldehyde (1, 5-pentanedialdehyde) (Glut) fixation has been the standard
since tissue bioprothestic valves became clinically available in 1970. Glut crosslinking
forms Schiff base bonds with the primary amines of amino acid resides lysine and
hydroxylysine on collagen, while other extracellular matrix components lack the amine
functionalities required for crosslinking [18, 82]. These degradation inhibiting bonds
render the tissue more stable against mechanical loading Glut also improves the tissue
antigenicity and makes the tissue thromboresistant eliminating the need for
anticoagulation treatment [18, 82]. To some extent Glut will sterilize the tissue against
bacteria, fungi, and viruses, but depends on the concentration, pH, temperature and
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duration of the fixation [83]. At low concentrations Glut has poor anti-bacterial and antifungal properties [84]. Disadvantages of Glut crosslinking include the cytotoxic effects
and the ability to induce calcification [31]. Physical changes and autolysis are also
complications with the use of Glut [18, 82]. Treated bioprosthetic tissue varies from
native healthy tissue in that there is a loss of surface endothelium or mesothelium, bovine
interstitial cells undergo autolysis, collagen bundles loosen, and there is a loss of GAGs
[85]. Glut crosslinking does not stabilize GAGs and they are lost after storage from
porcine aortic heart valves [1]. Glut fixation eliminates the tissues’ natural ability to
remodel and scavenge cell debris making it more susceptible to mineralization.

In

complete binding also leaves aldehyde residuals which are cytotoxic. Glut’s ability to
induce calcification and ultimate failure is the main challenge with bioprosthetic heart
valves that remains to be eradicated.

1.7 Anti Calcification Technologies
There are three main approaches to anti-calcification treatment, systemic therapy,
local therapy or drug delivery, and modification biomaterials.

Systemic therapy by

diphosphonates has been explored; however, they interfere with physiologic calcification
in normal bone growth [86]. Local delivery of ethane hydroxybisphonate was successful
at reducing calcification with limited undesirable effects [87, 88].
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1.7.1 Modification of Biomaterials
Modification of biomaterials is the main approach taken to prevent calcification
either by treating the glut fixed tissue or using an alternative fixation. Anti-calcification
modifications to glut fixed tissue include the use of diphosphonates [87], metal ions such
as aluminum and iron [89-91], amino-oleic acid [92, 93], surfactants such as sodium
dodecyl sulfate to remove acidic phospholipids [94], and incubation in ethanol [14, 95].
Ethanol pre-treatment prevents calcification by removing phospholipids and cholesterol,
but permanently alters the conformation of the collagen [14, 95]. More recent research
shows that the use of octanol storage after glut fixation preserves the collagen triple
helical structure unlike ethanol, but does not compare the ability to reduce calcification
[96]. Multiple stage anti-calcification fixation with ethanol pretreatment, glut fixation,
followed by detoxification with L-glutamic acid monosodium salt and extraction of lipids
by chloroform and methanol resulted in a significant reduction of calcification with less
visible changes to the structure and improved stability [97].

Decellularization is another

means of reducing calcification by removing the entire cell as mineralization begins in
the phospholipid membranes of non-viable interstitial cells [39, 98]. Removal of cells
may only reduce initial calcification as host cells infiltrate the tissue and become
devitalized.

1.7.2 Alternative Fixation Chemistries
Modified and alternative fixations have sought to find better means for sterilizing
bioprosthetic tissue with out the toxic effects of Glut. The key requirements for such
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fixations include that they must be effective in preventing adverse effects, systemic and
local toxicity, thrombosis, infection, immune response, and structural deterioration.
Fixation must also not alter normal valve hemodynamics [18]. Modification to the
fixation process to include lysine treatment neutralizes glut residues and reduces
calcification [99-102]. Alternative crosslinking chemistries include the use of epoxides,
carbodiimides, and acyl azides which reduce the calcification of tissue [18, 95, 103-106]
Triglycidylamine (TGA), a poly-epoxide, treated tissue has improved stability and
biomechanical properties compared to glut fixed tissue, but still some calcification [107].
TGA fixation inconjunction with 2-mercaptoethylidene-1, 1-bisphosphonic acid
treatment eliminates calcification in long term implants [108]. Other novel means of
fixation of tissue for implantation include photo-oxidative crosslinking [109-111] and
ultraviolet light treatment [112].
The role of GAGs in preventing bioprosthetic tissue calcification is not entirely
known, but studies have found that with preservation of GAGs there is a reduction in
tissue calcification. Alternative crosslinking with the addition of glycosaminoglycans has
proved to reduce calcification [113, 114]. GAG targeted fixation has been accomplished
by pre-treating tissue with sodium periodate which resulted in reducing calcification[77].
Further studies have shown that with carbodiimide/N-hydroxysuccinimide (EDC/NHS)
treatment GAGs were preserved, but there calcification was still significant [80]. With
the addition of neomycin sulfate pretreatment to EDC/NHS glut crosslinking,
significantly more GAGs were retained in porcine tissue, however calcification was not
completely reduced [81].

26

CHAPTER TWO
EXPERIMENETAL PLAN

2.1 Research Hypothesis
Previous studies have shown that Glut cross-linking does not stabilize
glycosaminoglycans (GAGs) and that GAGs are lost from porcine bioprosthetic heart
valves [1]. We hypothesize that Glut does not stabilize GAGs in pericardium and loss of
GAGs may play a role in the degenerative failure of pericardial valves. Also stabilizing
GAGs in the extracellular matrix of the pericardial valves may improve their function and
extend their life. To evaluate these hypotheses, this work was divided into four specific
aims.

2.2 Research Aims
Aim 1: To characterize bovine pericardial tissue structure, and to determine
the contribution of glycosaminoglycans to the structure and mechanical behavior of
the tissue. Characterization of the extracellular matrix and GAGs of the tissue at four
specific sites was conducted by histological staining. The site specific GAG content and
disaccharides present were also assessed.
The structure of the matrix and presence of GAGs was examined through
transmission electron microscopy.

Total GAG and hexosamine values were also

quantified. The role of GAGs was evaluated through mechanical testing before and after
treatment with GAG degrading enzymes.
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Aim 2: To determine the effectiveness of glutaraldehyde fixation in retention
of glycosaminoglycans. The retention of glycosaminoglycans after fixation and storage
in Glut as well as the resistance to GAG degrading enzymes were quantified.

Aim 3: To determine the effectiveness of glycosaminoglycan stabilizing
fixation. The effect of Neomycin trisulfate on the stability of glycosaminoglycans was
examined. Also stability and resistance to enzyme were evaluated after fixation and
storage. Finally, the effect of Neomycin on pericardial tissue properties including the
water content, collagen stability, and elastin stability were investigated.

Aim 4: To determine the stability of glycosaminoglycans in vivo and
correlation with calcification.

Subdermal implantation of cross-linked tissue was

performed to evaluate the calcification of tissue as well as the retention of
glycosaminoglycans.
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CHAPTER 3
MATERIALS AND METHODS

3.1 Materials
Ammonium acetate, neomycin trisulfate salt hydrate, glutaraldehyde (50% stock),
hyaluronidase (from bovine testes, type IV-s, 3,000–15,000 U/mg), chondroitinase ABC
(from Proteus vulgaris, lyophilized powder, 50–250 Umg), D(+)-glucosamine-HCL,
collagenase Type VII from Clostridium histolyticum, 1-9- dimethylmethylene blue
(DMMB) were all purchased from Sigma-Aldrich Corporation (St. Louis, MO). 1-ethyl3-(3-dimethylaminopropyl) carbodiimide (EDC), n-hydroxysuccinimide (NHS) were
acquired

from

Pierce

Biotech

(Rockford,

IL).

Acetyl

Acetone,

p-dimethyl

aminobenzaldehyde, and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
were bought from Fisher Scientific (Fair Lawn, NJ). 4-morpholinoethanesulfonic acid
hydrate (MES) hydrate was purchased from Acros Organics, NJ.

Fresh bovine

pericardial tissue was obtained from a local abattoir, Snow Creek Meat Processing,
Seneca, SC.
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3.2 Methods

3.2.1 Bovine Pericardium Collection and Fixation
Fresh bovine hearts, with pericardium intact, were collected from a local
abattoir. The pericardial tissue was dissected removed from the heart by cutting along
the base of the heart, leaving the remaining tissue intact, and transported to the laboratory
in un-buffered saline.

The tissue was rinsed, and trimmed of external fat in the

laboratory.
Glutaraldehyde fixed bovine pericardium (GLUT) was prepared by fixing the
fresh tissue (within 4 hours of collection) in 0.6% glutaraldehyde. Fresh pericardium was
placed

in

0.6%

glutaraldehyde

in

50

mM

HEPES

(4-(2-hydroxyethyl)-1-

piperazineethanesulfonic acid) buffered saline solution at a pH of 7.4 for 24 hours. The
tissue was then transferred to 0.2% glutaraldehyde in HEPES buffered saline for storage
at room temperature.
Carbodiimide treated bovine pericardium (EDC) was fixed using 1-Ethyl-3-(3dimethylaminopropyl) carbodiimide HCL (EDC) and N-Hydroxysuccinimide (NHS).
Fresh pericardium was immersed in a 30mM EDC/ 6mM NHS solution buffered with
50mM MES at pH 5.5 for 24 hours at room temperature. After 24 hours fixation the
tissue was rinsed , fixed and stored with the standard GLUT fixation.
Bovine pericardium was treated with glycosaminoglycan stabilizing agent,
Neomycin Trisulfate (NEO) for 1 hour. Fresh tissue was covered with 1mM Neomycin
in – buffer at a pH of 7.4. After one hour the tissue was rinsed and then fixed in 30mM
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EDC/ 6mM NHS for 24 hours, followed by standard fixation and storage in
glutaraldehyde.
For site specific studies the fresh bovine pericardium was oriented based on the
pericardiodiaphragmatic attachments and the sternopericardial ligaments and cut into four
regions as shown below in figure 10 [34]. The four regions were defined to be Posterior
Left Ventricle (PV), Posterior Right Ventricle (PR), Anterior Right Ventricle (AR), and
Anterior Left Ventricle (AL).

Figure 10: Schematic diagram of bovine pericardial excision and orientation [34]

3.2.2 Enzymatic Removal of Glycosaminoglycans
Pericardial tissue was removed from storage solutions and samples were punched
out using a 5/16’’ diameter die. The pericardial disks were then rinsed in 100mM
Ammonium Acetate buffer (pH 7.0). GAGs were removed from the tissue by incubating
the samples in 1.2 ml of 10 U/ml hyaluronidase and 0.2 U/ml high purity chondroitinase
ABC in 100mM Ammonium Acetate buffer. Undigested samples as controls were placed
in 1.2mL of Ammonium Acetate buffer. All samples were shaken at 650 RPM for 48
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hours at 37°C. After incubation, the samples were rinsed three times in distilled water.
The tissue was then frozen at -80°C for one hour and then lyophilized for at least 24
hours.

3.2.3 Quantification of Glycosaminoglycans by Hexosamine Assay
Lyophilized tissue was weighed to obtain the dry tissue weight. Samples were
then hydrolyzed in 2 ml of 2M HCl for 20 hours at 95°C. After hydrolysis, the samples
were dried under nitrogen gas flow in a boiling water bath until only a brown residue
remained in the glass tube. Glucosamine HCL standards (0 – 200 µg/sample) were
prepared in 1M NaCl for a total volume of 2 ml. The sample hydrolysates were also
dissolved in 2 ml of 1 M NaCl. 2 ml of 3% Acetylacetone in 1.25 M Sodium Carbonate
was added to all samples and standards and heated for 1 hour at 96 C. After cooling to
room temperature, 4 ml of 100% ethanol was added, and followed by the addition of 2ml
of Ehrlich’s reagent (0.18M p-dimethylaminobenzaldehyde in 50% ethanol containing
3N HCL). The samples were kept for 45 minutes at room temperature before measuring
optical absorbance at 540 nm on a microplate spectrophotometer ((µQuant, Biotek
Instruments Inc., Winooski, VT).

The total hexosamine content was calculated by

comparing the absorbance values to a set of linear D(+)-glucosamine standards (0-200
per 2 ml). All sample values were normalized by the dry tissue weight. Six samples per
group were used unless stated otherwise.
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3.2.4 Quantification of Glycosaminoglycans by Uronic Acid Assay
Pericardial GAGs were extracted and quantified from 5/16’’ diameter samples by
using a uronic acid assay[115, 116]. GAG enzyme treated and un-treated samples were
frozen in liquid nitrogen and pulverized into a small pellet. The pellet was then frozen at
-80°C for one hour and then lyophilized for at least 24 hours.

Lyophilized tissue was

weighed to obtain the dry tissue weight. GAGs were extracted from the tissue in 1ml of
0.5N sodium hydroxide at 4°C while shaking at 750 rpm for 24 hours, followed by the
addition of 0.5 ml of 30% Trichloroacetic Acid to precipitate proteins while shaking at
500 rpm at 4°C for 24 hours. The GAG suspension was then centrifuged for 12 minutes
at 12,000xG to remove the tissue and precipitate proteins. The supernatant (3500 MW)
was dialyzed against several changes of water at room temperature for 24 hours to
remove TCA. The remaining GAG solution was transferred to a glass test tube by adding
10% Cetylpyridinium Chloride (final concentration of 5%) and incubated at 37°C for 24
hours to precipitate the GAGs. The GAG precipitate was collected by centrifuging the
suspension at 2000xG for 15 minutes and dissolved in 3ml of 10% sodium acetate.
GAGs were reprecipitated with 12 ml of 100% ethanol at -20°C for at least 48 hours.
The pure GAG extract was finally collected by centrifugation at 2000xG for 15 minutes
and dried in hood overnight or under nitrogen at room temperature.
The extracted GAGs were quantified colorimetrically to detect uronic acid, which
is a component of all GAGs except keratin sulfate[115].

The dried GAGs in the

unknown samples were dissolved in 1 ml of benzoic acid saturated water, followed by the
addition of 5ml of Borax decahydrate (25mM) in 36 N Sulfuric Acid mixed in a dry ice
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and acetone bath. After vortexing to ensure good mixing the unknown samples were
placed in a boiling water bath for 10 minutes, and cooled to room temperature. After
adding 0.2 ml of carbazole reagent (0.125% carbazole in 100% ethanol), samples were
placed back into the boiling water bath for 15 minutes, and cooled to room temperature.
Optical absorbance was measured using a microplate spectrophotometer (µQuant, Biotek
Instruments Inc., Winooski, VT). Quantitative values for uronic acid content were found
by comparing the unknown samples with a set of glucuronolactone standards (0 – 25 µg
per ml) prepared similarly except that the carbazole reagent was added before heating,
and then heated once for 25 minutes. All values were normalized to the dry tissue weight
for comparison. Six samples per group were used (n=6).

3.2.5 Tensile Testing
Fresh pericardial tissue was cut into dogbone-shaped samples with dimensions
(30mm length x 5 mm width x ~ .5 mm thickness). Half of the samples were digested by
GAG degrading enzymes as described earlier.

Ten samples per group were tested

(n=10). The samples were then placed it the grips of the MTS (Synergie 100) machine
and cycled five times up to 10% strain at a speed of 0.2 mm/s. Displacement and load
were recorded, and were then used to calculate and plot the stress and strain for cycles 2
through 5. The modulus was calculated as the slope from the linear region (0-2%) of the
stress-strain curve. Hysteresis was also calculated as:
h=

(loading - unloading area)
loading area
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3.2.6 Flourophore-Assisted Carbohydrate Electrophoresis
Assessment of the GAG disaccharides was performed based on the methods of
Calabro [117]. Fresh pericardial tissue was cleaned, rinsed in de-ionized water, and
samples were punched out using a 5/16’’ diameter circular die. Four punches per sample
were minced, frozen and lyophilized in pre-weighed 1.5 ml centrifuge tubes. The dry
weight was recorded after 24 hours of being lyophilized, as 10 to 12 mg of dry tissue was
needed. For every 3 mg of dry tissue 1ml of 100 mM Ammonium Acetate Buffer (pH
7.0), and 100 µl of Proteinase K (10mg/ml) were added. The tissue incubated at 60°C for
16 hours, and boiled for 10 minutes to stop digestion. Samples were then centrifuged at
1200 rpm for 10 minutes to separate supernatant. A volume of 200 µl was aliquoted per
sample and placed into the filter portion of a Microcon YM 3 tube (Fisher) and
centrifuged at 9000 xG for 25 minutes.

The retentate was recovered in 100 µl of

Ammonium Acetate Buffer (pH 7.0), and the protein amino-acids (flow-through)
discarded. The GAG solution was then digested with hyaluronidase and chondroitinase
ABC (5mU/sample) for 22 hours at 37°C, and boiled for 10 minutes to stop. The
samples were centrifuged again at 9000 xg for 25 minutes through Microcon YM 3
filters, and the flow-through or disaccharides were retained. Chondroitin Sulfate and
Hyaluronic Acid disaccharide mixture was prepared as standards (1000 pmoles). To the
lyophilized GAG standards and samples, 40 µl of Aminoacridone fluorotag (20mM
AMAC in 3:17 HAc: DMSO) were added and kept at room temperature for 15 minutes.
A volume of 40 µl of 1.25 M NaCNBH3 was added before incubated at 45 °C for 2 hours.
Monosaccaride running buffer and gel (kit – company name here) were prepared and
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stored at 4 °C overnight. Loading buffer (20 µl) and tracking dye (2 µl) were added to
samples (20 µl) before placing 18 µl into each well. The gels were run at 500 V for 80
minutes at 4 °C. The fluorescent bands were then photographed under ultraviolet light,
and lanes were analyzed by densitometry. Two samples per group were used.

3.2.7 Water Content
The water content of fresh and fixed bovine pericardium, before and after
enzymatic digestion of GAGs, was determined by weight analysis. After enzyme
incubation, the samples were rinsed, blotted gently to remove excess water, and wet
weight was recorded. The tissue was then lyophilized for 24 hours and the dry weight
was measured. The percent water content (WC) was calculated as:
% WC = [(wet weight – dry weight)/wet weight] x 100

3.2.8 Collagen and Elastin Stability
The collagen stability in cross-linked bovine pericardium was determined by
measuring the resistance to collagenase as well as the thermal denaturation temperatures
(Td) for tissues fixed with GLUT, EDC, and NEO respectively. Differential Scanning
Calorimetry (DSC) (Model DSC 7, Perkin-Elmer, Boston, MA) was performed to
quantify Td (n=3 per group). Each sample was heated at a rate of 10°C/minute from 20 to
110°C, and the temperature at the endothermic peak was recorded (Td).
The resistance to collagenase was determined after fixation, samples were taken
of 5/16’’ in diameter from the sheets of pericardial tissue and rinsed with water. Samples

36

were then lyophilized and weighed to attain the initial dry weight prior to digestion with
collagenase. The collagenase enzyme (type VII) was prepared at 75 U/ml in a buffer of
50 mM Tris buffer, 10 mM CaCl2, and 0.02% Sodium Azide (NaN3) at a pH of 8.0. Each
sample was placed in a volume of 1.2 ml of the collagenase solution for 48 hours at 37°C
while shaking at 650 RPM. The resistance to elastase was determined in a similar
manner. Each sample was placed in 1.2 ml of 5 U/ml elastase dissolved in a buffer of
100mM Tris, 1 mM CaCl2, and 0.02% Sodium Azide (NaN3) at a pH of 7.8. for 24 hours
at 37 °C while shaking at 650 RPM. After freezing and lyophilizing the tissue, the dry
weight was once again recorded as the final weight. The weight loss was calculated as
follows:
Weight loss = [(Initial Weight – Final Weight)/Initial Weight] x 100

3.2.9 Subdermal Implantation
Bovine pericardial tissue fixed in GLUT, EDC and NEO (n=12/fixation group)
was cut into small diameter circles, and rinsed thoroughly with sterile saline prior to
implantation.

Male juvenile Sprague-Dawley rats (33-40 g, Harlan Laboratories,

Indianapolis, IN) were placed under general anesthesia by inhalation of 2-4% isofluorane
gas. A single, small incision was made in to the dorsal aspect of each rat, from which
two subdermal pockets were formed. A single pericardial tissue sample was placed into
each pocket and then the incision was closed with surgical staples.

The rats were

humanly euthanized after 21 days using CO2 asphyxiation; samples were removed and
prepared for analysis. The following diagram (Figure 11) illustrates how the tissue was
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prepared and analyzed. All animals received humane care in compliance with protocols
approved by Clemson University Animal Research Committee and the National Institutes
of Health (Publication No. 86-23, revised 1996). Samples for calcium analysis and GAG
quantification were immediately frozen on dry ice after sacrifice.

Samples for

histological studies were placed in 10% alcoholic acid formalin at ambient temperature.
Analysis of GAG content was content was carried out on a section of each explanted
sample by hexosamine quantification as previously described.

Figure 11: Subdermal implant samples; this schematic indicates how each sample was
divided for study. Hexosamine was performed on tissue for GAG quantification.
Calcium analysis was also performed on the tissue, and Histology was also performed to
examine the tissue calcification and GAG content qualitatively.

3.2.10 Calcium Analysis
Calcium analysis was completed on one section of the lyophilized explanted
tissue after obtaining the dry tissue weight for normalizing the data. The dried tissue was
hydrolyzed in 1ml of 6N Ultrex II hydrochloric acid for 8 hours in a boiling water bath.
After hydrolysis, the samples were dried under a continuous flow of Nitrogen gas, and re-
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suspended in 1 ml of 0.01 N Ultrex HCl.

Hydrolyzed samples were then centrifuged

before making the appropriate dilutions in an Atomic Absorption Matrix (0.3N Ultrex
HCl and 0.5% Lanthanum Oxide). The calcium content of each sample was acquired by
atomic absorption spectroscopy on Perkin Elmer AAnalyst200 Atomic Absorption
Spectrometer.

3.2.11 Transmission Electron Microscopy
To examine the extracellular matrix at the fibril level and to observe GAGs
transmission electron microscopy analysis was performed on fresh as well as fixed tissue.
Tissue preparation was executed as described by Simionescu [118]. Briefly small 1 mm2
fragments of tissue were cut and stored in Karnowsky’s fixative (2.5% glutaraldehyde
EM grade, 2% formaldehyde histology grade, in 0.1M cacodylate buffer, pH 7.4) at room
temperature. The tissue was then placed in 5-10 ml of 2% glutaraldehyde EM grade,
0.2% toluidine blue in 0.1M cacodylate buffer (pH 7.4) overnight at 4 C. Samples were
then rinsed in 0.1% Toluidine Blue in 0.1M cacodylate buffer pH 7.4 at room
temperature and then treated with 1% OsO4 (EM grade) in 0.1M cacodylate buffer with
0.1% Toluidine Blue (pH 7.4) for 60 minutes at room temperature. After treatment with
OsO4, the tissue was rinsed with 0.1M cacodylate buffer (pH 7.4) and dehydrated
through an increasing series of ethanol. The samples were then transferred to propylene
oxide and embedded in PolyBed 812. Ultra-thin sections (100nm) were cut from the
middle portion of samples, collected on copper grids, and stained with 2% uranyl acetate
followed by Hainaichi Lead stain.

Grids were examined on a Hitachi H7000
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transmission electron microscope at 100kV.

Toluidine blue stains all GAG species

effectively, and appear as fine filaments at the TEM level [118].

3.2.12 Histological Analysis
Representative samples were taken from fresh, fixed as well as explanted fixed
bovine pericardium, and fixed in alcoholic acid formalin for 24 hours, embedded with
paraffin, and sectioned at a thickness of 5 µm. To qualitatively examine the extracellular
matrix components, Gomori’s One Step Trichrome stain was used. Elastin fibers were
observed by staining with Verhoeff’s stain for Elastic Tissue. Alcian blue staining with
Brazilliant!® nuclear fast red counterstain were used to detect GAGs.

Quantitative

calcium analysis was also performed on explanted tissue from subdermal implant study
by staining with Alizarin Red and Fast Light Green counterstain by Dahl’s Method for
Calcium. A Zeiss Axioskop 2plus microscope was used with SPOT Advanced software
to obtain histological images.

3.2.13 Statistical Analysis
The results presented are reported as a mean with the standard error of the mean
(SEM). Comparisons between groups were done by analysis of variance (ANOVA) as
well as two-tailed student’s t-test of unequal variance. Significant differences were
defined with p< 0.05.
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CHAPTER 4
RESULTS

4.1 Bovine Pericardial Tissue Structure
4.1.1 Site Specific Characterization
The structure of the pericardial extracellular matrix was evaluated at four specific
sites overlying the posterior left (PL), posterior right (PR), anterior right (AR) and
anterior left (AL) ventricles as previously described. Histological staining specific for
elastin, collagen and glycosaminoglycans was done as shown in figures 12, 13 and 14
respectively. Elastin fibers are interwoven with collagen bundles and account for only a
portion of the matrix as seen in figure 12. Staining with Gomori’s trichrome confirms the
presence of collagen (green) as the main component of the extracellular matrix. The
collagen appears discontinuous in several sections as the bundles are in cross section. No
significant differences between sites could be distinguished with only qualitative
evaluation.
Alcian blue stain for glycosaminoglycans was conducted to qualitatively assess
the GAG content of bovine pericardium by site. Blue areas are clearly seen on the edges
of the sections in figure 12, but this could be due to edge affects. Some diffuse blue can
also be seen throughout the tissue, but quantitative studies are needed for verification of
the GAG content.

41

Figure 12: Verhoff’s van Gieson stain for elastin of bovine pericardial tissue. A & B
(PR), C & D (PL), E & F (AR), G & H (AL) at 200x and 400x magnification.
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Figure 13: Gomori’s trichrome stain for collagen of bovine pericardial tissue A (PR), B
(PL), C (AR), D (AL) at 200x magnification.

Figure 14: Alcian blue stain for glycosaminoglycans of bovine pericardial tissue A (PR),
B (PL), C (AR), D (AL) at 200x magnification.
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The hexosamine content was quantified in the posterior and anterior regions
above the right and left ventricles before and after enzyme treatment with Chondroitinase
and Hyaluronidase for 48 and 96 hours. In the first case, fresh non-digested pericardial
tissue was found to have significantly greater hexosamine content in the posterior regions
as compared to the anterior regions as shown below in Figure 15.

There was no

difference between groups after treatment with GAG degrading enzymes (p<0.05).

Figure 15: Site specific hexosamine content after 48 hours of enzyme digestion

For the second case, half of the tissue was treated with GAG degrading enzymes
for 96 hours to determine a baseline non-GAG related hexosamine value (Figure 16).
However, due to considerable variability there were no statistical differences between
groups or within groups after enzyme (n=5 and 6, p<0.05).

44

Figure 16: Site specific hexosamine content after 96 hours of enzyme digestion

To further investigate the GAG content at specific sites in the pericardium,
flourophore-assisted carbohydrate electrophoresis was conducted on GAGs extracted
from the tissue. Light bands of the gel correspond to Hyaluronic Acid (HA), 0-sulfated
(0-S), 6-sulfated (6-S) and 4-sulfated disaccharides (Figure 17). The most prominent
band corresponds to 4-sulfated disaccharides. This could be both chondroitin sulfate and
dermatan sulfate. Densitometry based on relative density units (RDU) results confirm
that this 4-sulfated GAG content is significantly greater than the other GAG types present
(Figure 16-A).

With an average of 6956 RDU/mg of dry tissue, 4-sulfated

glycosaminoglycans make up 80% of the total GAG content. HA, 0-sulfated and 6sulfated GAGs combined are 20% of the GAG content. (Figure 18-B) There was no
significant difference between the anterior right, anterior left, posterior right or posterior
left regions (p<0.05).
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Figure 17: FACE Electrophoresis Light bands indication hyaluronic acid, 0-sulfated, 6sulfated, and 4-sulfated disaccharides in flourophore-assisted carbohydrate
electrophoresis.

Figure 18: (A) Relative densitometry units per mg of dry tissue for GAG types in fresh
bovine pericardial tissue. (B) Average relative density units RDU/mg in fresh
pericardium.
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4.1.2 Glycosaminoglycans in Fresh Bovine Pericardium
To quantify the total GAG content of fresh bovine pericardium excluding nonGAG related hexosamines, uronic acid assay was performed before and after enzyme
digestion. With 13.5± 1.64 µg of uronic acid per 10 mg of dry tissue, and 8.56 ± 2.00 µg
of uronic acid per 10 mg of dry enzyme digested tissue (Figure 19). The 37% decrease in
GAG content, although not significant (p<0.05), indicates that complete GAG removal is
not obtained by Chondroitinase ABC (p. vulgaris) and Hyaluronidase after 48 hours of
incubation. When compared to Figure 20, the uronic acid content is approximately 13 %
of the total hexosamine content with 103.04±1.64 µg/10 mg of hexosamine in the same
tissue. Also of note is there is no significant difference after treatment with enzyme
suggesting incomplete digestion (p<0.05).

Figure 19: Micrograms of Uronic Acid per 10 mg of dry pericardial tissue after treatment
with Hyaluronidase and Chondroitinase
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Figure 20: Micrograms of hexosamine per 10 milligrams of dry fresh pericardial tissue
after enzyme treatment.

To further examine the presence of GAGs in bovine pericardium the fresh tissue
was examined under transmission electron microscopy. Fresh tissue was treated with
Toluidine blue, a GAG specific stain, and examined at different magnifications. Few
select locations were found to have darkly stained thin GAG fibers. GAGs were found in
the space between fibers, bordering elastin fibers, as well as connecting collagen fibers as
shown in Figure 21. Many GAG fibers were found at the surface of elastic fibers,
amongst elastin-associated microfibrils (Figure 21 A, B, and D). GAGs also appear as
bridges or connections between adjacent collagen fibers (Figure 21 E and F). In some
cases the collagen fibers appear in cross-section with GAG fibers connecting neighboring
fibers (Figure 21 A and C).

48

Figure 21: TEM of Fresh Pericardial Tissue A) Collagen fibers and elastin fringe with
thin spindle shaped fibers 30,000X B) Elastin fibers with fringe associated GAG small
fibers 20,000X C) 15,000X D) Elastin fringe with thin spindles (GAG) 20,000X E)
15,000X F) Same location as E at 40,000X magnification.

49

Resistance to tensile loading was conducted to evaluate the mechanical role of
GAGs in fresh bovine pericardium. Fresh pericardium, half of which was treated with
GAG degrading enzymes, was loaded to 10% strain and the modulus was calculated from
0 to 2% of the linear region as described earlier. Sample stress strain curves are shown in
Figure 22 show the extreme cases in each group as an indication of the variability. The
modulus was slightly lower for fresh non-digested tissue. Hysteresis, a measure of
viscoelasticity, was slightly lower after enzyme digestion.

There was, however, no

significant difference in modulus or hysteresis with or without GAG enzyme incubation.

Figure 22: Sample Stress Strain Curves (A & B) Fresh Pericardium Tensile Cycling
Sample (C & D) Enzyme Digested Pericardium Tensile Testing Sample

Table 4: Modulus and Hysteresis of Fresh Pericardium
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4.2 Glutaraldehyde Fixation Effectiveness
To evaluate the stability and retention of GAGs in glutaraldehyde fixed
pericardial tissue, the GAG content was assessed 14 days after fixation. FRESH and
GLUT fixed tissue was incubated in GAG degrading enzymes. After enzyme digestion
both groups showed a significant decrease in GAG content (p<0.05) with a loss from
81.02 ±6.70 µg/ 10 mg to 59.06 ± 3.50 µg/ 10 mg for fresh tissue and 81.63 ± 3.53 µg/ 10
mg to 59.06 ± 3.59 µg/ 10 mg for GLUT fixed tissue. There was no significant
difference between groups, indicating that glutaraldehyde cross linking does not stabilize
GAGs against enzyme degradation.

Figure 23: GAG stability after storage in Glutaraldehyde for 14 days
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To confirm GAG loss in the pericardial tissue, uronic acid assay was performed.
This method quantifies the uronic acid portion of the GAG as there are non-GAG related
hexosamines present in the tissue. As shown in the figure below the uronic acid content
is much less than the hexosamine content at 11 µg/10 mg of tissue of non-digested tissue.
After enzyme digestion a 40% decrease is seen (6 µg/10 mg, p<0.05).

Figure 24: Retention of GAGs in GLUT fixed pericardium after enzyme digestion

GAGs are not initially stabilized by glut fixation. To examine if GAGs continue
to be degraded over time the Gag content was quantified at 2 times points in the same
tissue at 14 days, and 5 months in GLUT. A significant loss of GAGs occurred between
14 days after fixation and 5 most storage (from 81.6 to 53.4) a 35% reduction. After
treating the stored tissue with GAG degrading enzymes the GAG content was decreased
even further to 35.6 µg/10 mg of dry tissue.
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Figure 25: Glycosaminoglycan stability after storage in Glutaraldehyde for 5 months

4.3 GAG Stabilizing Fixation Effectiveness
Neomycin trisulfate with EDC fixation followed by storage in GLUT was
examined as an alternative fixation for stabilization of GAGs. Three concentrations of
neomycin were used to stabilize the tissue. After quantifying the GAG content, there was
no significant different between the groups, with 85 to 90 µg of hexosamine per 10 mg of
dry tissue. 1mM NEO was selected because there was no significant difference.
To assess the stability and retention of GAGs, the hexosamine content was
measured before and after treatment with enzyme.

Although significant GAG loss

occurred in fresh and glut fixed tissue, no significant loss occurred in the NEO fixed
tissue, with 75 µg of hexosamine as compared to 59. Neomycin is able to retain and
stabilize GAGs against enzyme digestion.
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Figure 26: Effect of Neomycin Concentration

Figure 27: GAG stability with NEO and resistance to enzyme digestion
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After 5 months storage in glut the GAG content of NEO fixed tissue did decrease
but not as much as in GLUT fixed tissue. After enzyme digestion of 5 months storage the
NEO fixed tissue showed no significant decrease in GAG content from undigested tissue
at 5 months, while GLUT fixed tissue had a significant loss in GAG content. NEO has
improved GAG retention after 5 months storage.

Figure 28: GAG stability with NEO after 5 months of storage in Glut

GAG stabilization is improved by using NEO, but the properties of the tissue
should not be negatively affected. The water content indicates the tissue hydration and
viscoelastic potential. The tissue was exposed to GAG degrading enzymes to possibly
correlate the stabilization of GAGs with water content.

However, there was no

significant difference between the GLUT, EDC, and NEO fixations. In comparison with
fresh tissue, the water content was significantly greater in NEO fixed tissue after enzyme
digestion (p<0.05) indicating improved hydration with the stabilization of GAGs.
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Figure 29: Hydration, water content before and after enzymatic digestion

Stability of elastin and collagen in pericardial tissue was evaluated to ensure that
the properties of the tissue are not negatively altered. Tissue fixed with GLUT, EDC, and
NEO was treated separately with collagen and elastin degrading enzymes. The tissue was
weighed before and after treatment and the percent mass retained was calculated as
described earlier. There was no significant difference in percent mass retained between
any of the groups. Almost 99 to 100 percent of the tissue was retained after treatment
with collagenase and 96 to 97 percent after elastase indicating stable crosslinking of both
collagen and elastin. The stability of collagen was further examined by measuring the
thermal denaturation temperature by differential scanning calorimetry. The denaturation
temperature was significantly lower for GLUT fixed tissue than NEO indicating
improved crosslinking of collagen in pericardial tissue with NEO fixation.
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Table 5: Collagen and Elastin resistance to enzyme after crosslinking chemistry

Table 6: Thermal denaturation temperature after fixation

Transmission electron microscopy was also performed on crosslinked pericardium
to evaluate the presence of GAGs in the extracellular matrix, as well as the integrity of
the tissue. In Glut fixed tissue, few sites were found with dark staining fibers. The
majority of GAG fibers were found in the interfibrillar space as shown in figure 30.
Some of the GAG fibers were found connecting adjoining collagen fibers. Reduced
quantities of GAGs were observed at the surface of elastin as compared to the abundance
in fresh pericardial tissue (Figure 30 C and D).
For comparison, for EDC/NHS crosslinked pericardium was also evaluated by
TEM. GAGs were found in the space between extracellular matrix fibers as well as
bridging adjacent collagen fibers. Few were also found on the surface of elastin with the
elastin associated microfibrils. At higher magnification the characteristic spindle shape
of the GAG fibers can be seen.
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Figure 30: Glutaraldehyde fixed bovine pericardium transmission electron microscopy
images A) Thin filaments (darkly stained area) surrounded by collagen fibers at
15,000X; B) same as A at 30,000X magnification; C) Thin spindles darkly stained with
collagen fibers at 15,000X ; and D) same as C at 30,000X magnification.

GAG stability was also evaluated by TEM for Neomycin crosslinked pericardium.
GAGs were also only visible in select locations of the tissue indicating variable staining.
Dark stained fibers were found along the surface of elastin fibers as shown in Figure 32.
At higher magnificationi the spindle shaped fibers can clearly be seen in the interfibrillar
space.

The same location of the tissue can be seen in Figure 33, at 3 different

magnifications. GAGs are shown in the space between fibers as well as connecting
neighboring fibers. The anisotropic behavior of the tissue can also be seen in the varying
direction and alignment of the fibers.
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Figure 31: EDC/NHS crosslinked bovine pericardium as imaged under transmission
electron microscopy. A) Darkly stained thin spindles (GAGs) intertwined between
collagen fibers at 15,000X; B) same as A at 30,000X magnification. C) More thin
filaments (GAGs) surrounded by collagen fibers at 15,000X; D) same location as C at
30,000X magnification.

Figure 32: NEO treated bovine pericardium TEM images. Thin dark staining GAG
fibers A) at 15,000X and B) 30,000X magnification.
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Figure 33: NEO treated bovine pericardium examined under transmission electron
microscopy. Thin darkly stained fibers (GAGs) are found between collagen fibers at A)
15,000X, B) 30,000X and C) at 50,000X.
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4.4 GAG Stability in vivo and Correlation with Calcification

In vivo GAG stability was examined by quantifying the hexosamine content of
implanted and non-implanted tissue. There was no significant difference in hexosamine
content after implantation for 21 days.

This result was confirmed qualitatively by

histological study with Alcian blue stain. Overall only a diffuse blue is seen, similar to
the staining of fresh pericardial tissue.

Figure 34: Hexosamine content before and after subdermal implantation
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Figure 35: Un-implanted and implanted cross-linked bovine pericardium stained with
Alcian blue for GAGs A) GLUT un-implanted; B) GLUT implanted; C) EDC unimplanted; D) EDC implanted; E) NEO un-implanted; F) NEO implanted all at 25X
magnification.
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In an effort to correlate any role of GAGs with prevention of calcification, the
calcium content of the tissue was evaluated quantitatively and qualitatively. Atomic
absorption of diluted hydrolyzed tissue indicates that the calcium content was
significantly lower in EDC crosslinked pericardium in comparison to NEO, but there was
no significant difference from GLUT fixed tissue (p<0.05). There were 65 µg of calcium
per mg of dry tissue with 51 and 38 µg of calcium in GLUT and EDC fixed tissue
respectively.
Qualitative analysis of the implanted tissue for calcium was achieved by staining
with Alizarin red. The central region of all samples was dark red indicating the presence
of calcium in the tissue regardless of fixation method.

Figure 36: Calcium content of implanted cross-linked bovine pericardium
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Figure 37: Implanted cross-linked bovine pericardium stained with Alizarin red for
calcification A) GLUT at 25X; B) GLUT at 100X; C) EDC at 25X; D) EDC at 100x; E)
NEO at 25X; F) NEO at 100x.
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CHAPTER 5
DISCUSSION

Glycosaminoglycans are found in many tissues of the body including cartilage
and heart valve leaflets. They provide hydration and resistance to mechanical loading in
the extracellular matrix [119]. Research on the presence of GAGs in pericardium has
suggested that GAGs may play in important role in the dynamic mechanical properties of
bovine pericardium [2]. Their presence in bioprosthetic heart valves has been extensively
studied by our group. Studies have shown that Glut does not stabilize GAGs in porcine
aortic valves, and that GAGs continue to be lost over time and as well as after accelerated
fatigue testing [1, 61]. Alternative fixation with carbodiimide based crosslinking in
conjunction with Neomycin trisulfate has shown to improve the stability and resistance of
GAGs in porcine aortic valves [81]. As such, these indicate that the loss of GAGs may
play a role in the degenerative failure of pericardial valves and their preservation could
improve the durability and life of the valves.

5.1 Bovine pericardial tissue structure
5.1.1 Site Specific Characterization
The site specific GAG content was evaluated in two separate pericardial tissue
sacs after 48 and 96 hours. In the first case there were significantly more GAGs in the
posterior regions of the left and right ventricle. However, after enzyme digestion of 48
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hours there was no difference in hexosamine content between areas. In the second
pericardial sac the tissue was treated with enzyme for 96 hours, but there were no
significant differences in GAG content based on the origin of the tissue. Also the overall
hexosamine content was higher in the second sac with values ranging from 66.54±10.64
to 88.76± 4.72 µg of hexosamine per 10 mg of dry tissue as compared to 53.52± 3.24 to
72.74± 2.05 µg in the first sac. This indicates that the initial hexosamine content could
vary between 53 and 88 µg/10 mg depending on the tissue. This variation should be
taken into consideration with a higher sample number to accommodate the large possible
variability.
Numerous studies have examined the extracellular matrix components of the
pericardium with inter- and intra- sac variability, however, research has only been
conducted on the primary load bearing components of elastin and collagen. One study
found that the extensibility varied from site to site within the pericardial sac and was due
to the density of elastin in the tissue. They also found no significant difference in tissue
thickness between positions or sacs [27, 35]. Simionescu et al further mapped bovine
pericardial tissue by examining the fiber orientation, suture holding power, and
thickness[34]. With these criteria, they determined that the regions overlying the left
ventricle and superior aspect of the right ventricle were suitable for heart valve
fabrication. Another more quantitative method of Small Angle Light Scattering (SALS)
was developed to map the fiber direction and orientation [120]. Based on there research
the area overlying the left ventricle was the most ideal site for bioprosthetic use [32, 33,
120]. Although variability between sacs was highlighted as such one specific site will
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not have identical properties from sac to sac. It was suggested that the tissue be presorted based on fiber alignment where homogeneity and uniformity are crucial [32].
Several studies have attempted to map the tissue structure of bovine pericardium
to determine an ideal site for tissue selection; however they present varying conclusions
as to the area overlying the left ventricle [33, 34] and right ventricle [37]. The variability
of the matrix components, density, and alignment could be due to many factors including
breed, age, sex, weight, and environment of the animal [27, 31]. By increasing the
sample number and or using paired samples, inter- and intra- sac variability can be
accounted for.
Alcian blue stain for glycosaminoglycans was conducted to qualitatively assess
the GAG content of bovine pericardium by site. Blue areas are clearly seen on the edges
of the sections in figure 12, but this could be due to edge affects. Some diffuse blue can
also be seen throughout the tissue. The limited stain may also be due to the small
quantity of GAGs present, perhaps immunostaining specific for dermatan sulfate and
chondroitin sulfate would elicit better qualitative results[121-124].
Fluorophore-assisted carbohydrate electrophoresis of bovine pericardial tissue by
area further confirmed the presence of GAGs in fresh tissue.

Results also support

hexosamine data indicating there is no significant difference in GAG content between
sites. The most prominent GAG dissacharide present was 4-sulfated with over 80%.
These could be both chondroitin 4-sulfate and dermatan sulfate. Low amounts of 0sulfated and 6-sulfated dissacharides were present with only slightly higher presence of
hyaluronic acid. This correlates with published data which found the presence of a low
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molecular weight dermatan sulfate proteoglycan [40, 41]. Another, more recent, study
found dermatan sulfate, chondroitin sulfate and hyaluronic acid present in bovine
pericardium. 4-sulfated GAGs also dominated, however they found an absence of 6sulfated GAGs [2]. This variation could be due to variability in the tissue.

5.1.2 Glycosaminoglycans in Fresh Bovine Pericardium
GAG content
The GAG content was found by uronic acid irrespective of the site. The fresh
undigested content was 13.5 µg of uronic acid per 10 mg of dry tissue (Figure 19)
Comparing with published data, 11.78 µg of uronic acid were found, however this value
was based on 10 mg of wet tissue [2]. After enzyme digestion the uronic acid content
decreased by only 37%, indicating that Chondroitinase ABC (p. vulgaris) and
Hyaluronidase are not completely effective at degrading GAGs in bovine pericardium.
The GAGs in bovine pericardium, as presented earlier, are predominately Chondroitin 4sulfate and dermatan sulfate. Very small amounts of hyaluronic acid are present. The
activity of Chondroitinase ABC (p. vulgaris) is only 34 – 40% for dermatan sulfate [125].
Chondroitinase ABC from Flavobacterium heparinum has a 100% activity with
Dermatan, Chondroitin 4, and 6-Sulfate.
The uronic acid content when compared to corresponding hexosamine values
from the same tissue can provide an approximation of the baseline non-GAG related
hexosamine values. With nearly 103.04 µg of hexosamine per 10 mg, the uronic acid
content at 13.5 µg was only 13% of the total hexosamine content. Overall, the fresh
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tissue GAG content values are much lower than those found in porcine aortic valves, with
170 to 240 µg of hexosamine per 10 mg of dry tissue [1, 80, 126], and 150 µg of uronic
acid per 10 mg of dry tissue [1]. These results indicate that the majority of hexosamine
dissacharides present in the tissue are non-GAG related. Due to variability between
different pericardial sacs, a constant baseline of non-GAG hexosamine remains to be
found.
Visualization of GAGs in the ECM
Transmission electron microscopy of fresh pericardial tissue found few areas of
clearly stained GAGs. This could be due to incomplete staining or indication of the
structure of the tissue. The use of toluidine blue was selected because of its effectiveness
in porcine aortic tissue [118] however cuprolinic blue would provide better visualization
of GAGs in pericardium [41, 127].
Biomechanical Role of GAGs
The biomechanical role of GAGs in pericardium was investigated through cyclic
tensile testing; however no significant conclusions could be made. There were significant
variations in the overall stiffness of the tissue within groups due to variability in the
collagen fiber alignment and anisotropy of the pericardial tissue. After digesting the
tissue with Chondroitinase ABC (p. vulgaris) and hyaluronidase, no significant difference
was found in the hysteresis or modulus. The role of GAGs in pericardium was studied by
Mavrilas et al by dynamic mechanical tensile testing. They also found no significant
difference in mechanical properties by removing GAGs [2]. These results could be due
to incomplete digestion of the dermatan sulfate in the tissue or limited by the testing
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[125]. Flexural three-point bending of pericardium has reported to evaluate the
mechanical properties of bovine pericardial tissue and the effects of various crosslinking,
however, the effect of GAG loss or preservation has not been examined [46].

5.2 Glutaraldehyde Fixation Effectiveness
The use of glutaraldehyde to process and sterilize bioprosthetic valves continues
to be the conventional treatment despite the failure of valves by calcification and
structural deterioration. Glut is also limited in its ability to stabilize GAGs against
enzyme digestion and loss after long term storage. After digestion significant decreases
in GAG content were found for both fresh and Glut fixed bovine pericardium after 14
days of fixation. Even further loss was found after storage in Glut for 5 months. Similar
results were found in porcine aortic bioprosthesis [1]. As the uronic acid content or total
GAGs in glut fixed pericardium is approximately 12 µg/ 10 mg of dry tissue, the decrease
in hexosamine is much greater than the uronic acid content. This suggests that even nonGAG related hexosamines are lost and other extracellular matrix components are
becoming denatured. If Glut fixed tissue valves remain on the shelf even 5 months GAG
loss will occur prior to implantation.

5.3 GAG Stabilizing Fixation Effectiveness
5.3.1 GAG Content
The loss of GAGs from porcine bioprothesthic valves has been shown to reduce
the mechanical durability of the tissue [1]. Stabilization of GAGs was achieved by
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alternative crosslinking with carbodiimide fixation, however carbodiimide was not able
to retain all GAGs [80].

1-Ethyl-3-(3 dimethylaminopropyl) carbodiimide (EDC)

activates carboxylic groups of GAGs for reaction with free amine groups. The addition
of N-hydroxysuccinimide (NHS) increases the number of crosslinks, and limits
hydrolysis by increasing the number of activated carboxylic groups. These activated
carboxyl groups form amide crosslinks with free amine groups of collagen [128]. The
carboxylic groups of the uronic portion in GAGs are the active sties fro enzyme
degradation [125, 129]. Carbodiimide crosslinking does not stabilize all GAGs as some
carboxyl residues remain available for enzyme degradation [80].
The incorporation of Neomycin (1mM) with EDC/NHS crosslinking has
previously been evaluated for stabilization of GAGs in porcine aortic bioprostheses [81].
Three concentrations of NEO were evaluated to determine the stability of GAGs after
treatment with hyaluronidase and chondroitinase. There was no significant difference in
hexosamine content at a factor of 10 less and greater than 1mM, as such 1mM was used
for further testing. However, lower concentrations may be feasible based on the reduced
quantity of GAGs and sites for binding in the tissue. Neomycin trisulfate, a sulfated
oligosaccharide, has been demonstrated to prevent the degradation of hyaluronic acid by
various hyaluronidases [130]. Neomycin also has amine functionalities to react with the
remaining GAG residues. Neomycin coupled with carbodiimide and glut fixation shows
improved stability of GAGs after enzyme as well as after five months storage in glut.
This data is supprted by earlier studies that present that NEO prevents the degradation of
GAGs in porcine aortic tissue [81].
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5.3.2 Tissue Properties after GAG Stabilization
Glutaraldehyde has exhibited the ability to reduce the hydration of aortic cusps,
and hydration of porcine leaflets has been demonstrated to have an affect on the internal
shear properties of the tissue with increased hysteresis and stress relaxation [131-133].
Although pericardial leaflets do not have distinct layers like the spongiosa which can
accommodate large shear strain, the tissue exhibits similar shear modulus in fresh tissue
as compared to porcine cusps. After glut fixation the shear modulus of pericardium
increased similar to porcine aortic valves [44]. The water content of pericardial tissue
was measured as an indication of the tissue hydration, which showed no significant
difference after fixation. Enzyme digestion was performed to examine if a loss of GAGs
would affect the hydration capability of the tissue.

However, only fresh tissue

experienced a decrease in water content with GAG loss. This varies from other data
indicating that the water content of porcine cusps decreased with fixation [134]. This
variation could be due to variation in tissue structure. By stabilizing GAGs in the tissue,
the bulk and or bound water content was not affected in pericardial tissue.
The structural integrity of pericardial tissue is vital to the performance of
bioprosthetic heart valves. Collagen fibers form bundles which provide the architectural
framework and mechanical strength of the tissue. The collagen network of pericardium is
structure in which the orientation of undamaged collagen is key to the mechanical
properties and durability of the tissue [46, 47]. Degeneration of the collagen and elastin
network leads to mechanical failure as well as increase the potential for calcification
[135]. The results presented here indicate that after fixation all groups have improved or
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similar stability of collagen and elastin as Glut fixed pericardium. After treatment with
collagenase and elastase there was no significant difference between fixation groups.
The percent mass retained after collagenase was higher for pericardial tissue than that of
similar studies of porcine cusps [80].

The thermal denaturation temperature also

provides information as to the stability of collagen. The temperature oat which collagen
is denatured occurs once the triple helical structure becomes a random coil.

The

temperature is higher with increasing intra-helical and intermolecular crosslinking [136].
Glut fixed pericardium had a significantly lower denaturation point, indicating a higher
degree of crosslinking after carbodiimide and neomycin treatment. After treatment with
carbodiimide and neomycin cusps also had a slightly higher denaturation temperature
compared to just Glut, but the difference was not significant [81]. The values found are
within the same rants as those found by other studies with pericardium [136] and porcine
cusps [80]. After treatment with carbodiimide and neomycin cusps also had a slightly
higher denaturation temperature compared to just Glut, but the difference was not
significant [81].
Evaluation of the ultra structure by transmission electron microscopy did not
indicate any significant differences between fixation groups for the GAG content or
structure. Staining with Toluidine blue revealed small filaments near collagen fibrils as
well as some near the surface of elastin. Differences were apparent between fresh and
crosslinked tissue. Fewer GAGs were found near elastin fibrils; however this could be
due to inadequate staining.

Study of the dermatan sulfate proteoglycan in bovine

pericardium presented similar images as reported here. Staining with Cuprolinic blue
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revealed small fibers associated with collagen fibrils sometimes resembling spikes [41].
In depth evaluation of the GAG content in porcine cusps found damage in the
extracellular matrix, and loss of GAGs between and along the surface of collagen fibers
after Glut fixation [118].

5.4 In Vivo GAG Stability and Correlation with Calcification
Bioprosthetic valves implanted in the body ultimately fail due to calcification and
structural deterioration.

Examination of failed valves has shown fragmentation of

collagen bundles, mineralization of the tissue, damage as a result of mechanical fatigue,
and GAG loss [18, 60]. It is suggested that GAGs present in the connective tissue
inhibit calcification of the extracellular matrix by occupying space in the matrix, and
binding free calcium ions preventing the formation of calcification [135, 137]. The rat
subdermal model has been the standard means of evaluating the potential of a biomaterial
for calcification in the body [138, 139]. Numerous studies have been conducted to
evaluate the role of GAGs in calcification of bioprosthetic valve tissue. GAGs have been
removed, stabilized, and added to the prosthetic heart valve tissue in attempt to evaluate
the role of GAGs in calcification. Extraction of proteoglycans from BP resulted in lower
thermal stability and increased calcification [140].

Grafting hyaluronic acid to the

structure of glutaraldehyde fixed bovine pericardium reduced calcification [79].
Periodate stabilization of endogenous GAGs and crosslinking of exogenous Chondroitin
Sulfate resulted in significant reduction of calcification in bovine pericardium [78]. In
the present study GAGs were stabilized with neomycin and EDC pre-treatment, however
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there was no reduction in calcification. Earlier studies by our group on porcine tissue
treated with periodate and EDC found similar results in that there was no significant
difference in calcium content as compared to glut [80]. Also in the present study the
calcium content was significantly higher in tissue treated with Neomycin as compared to
EDC/NHS treated tissue. Neomycin pre-treatment of porcine aortic tissue, however,
showed a reduction in calcium content compared to glut after implantation [81].
Correlation of the GAG content with the calcium content is not conclusive. There
was no change in GAG content in any of the groups after 21 days. Previous studies have
found increased hyaluroidase and chondroitinase activity and significant GAG loss in
subdermal implanted porcine aortic cusps after 21 days [16, 80, 126]. It is possible that
with longer implantation times substantial GAG loss may occur as the GAG
disaccharides found in bovine pericardial tissue are different from those of the porcine
aortic leaflet as well as having different structure.
Although the role of GAGs in the prevention of calcification remains unclear, it is
certain that bioprosthetic valve tissue calcifies despite the stabilization of GAGs. The
methods presented here all involve the continued use of Glut, as such it can be assumed
that GAG stabilization has a limited potential to prevent the calcification of tissue and
toxicity caused by Glut.
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CHAPTER 6
FINAL CONCLUSIONS AND RECOMMENDATIONS

6.1 Conclusions
Advances in the design of bioprosthetic heart valves are such that at optimum
conditions, will fail after 10-15 years.

Glutaraldehyde has dominated as the single

fixative used for commercially available tissue valves. These studies indicate that:


GLUT fixation alone does not stabilize GAGs in bovine pericardium from
enzyme degradation or loss in storage.



Neomycin combined with EDC/NHS has enhanced standard Glut cross linking to
include the stabilization of GAGs.



Tissue properties of NEO fixed pericardium are not negatively altered after
fixation.



Tissue treated with Glut still has significant levels of calcification even with the
addition of NEO and EDC/NHS.
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6.2 Recommendations for Future Studies
Tissue variability has widely been explored as to the optimum site of pericardial
tissue for bioprosthetic use, however no investigations to date have include analysis of
the proteoglycan and glycosaminoglycan content variability.

Future studies could

investigate more in depth the content by using multiple pericardial sacs from bovine of
equivalent age, sex, and weight.
Limited visualization of GAGs was achieved by Alcian blue with histology and
Toluidine Blue with TEM. The limited stain may be due to the small quantity of GAGs
present, future evaluation of bovine pericardium should include immunostaining specific
for dermatan sulfate and chondroitin sulfate [121-124].
The role of GAGs in pericardial bioprosthetics remains to be elucidated.
Physiologically relevant mechanical testing of pericardium with intact extracellular
matrix as compared to completely degraded GAGs is needed. The use of alternative
enzyme may ensure complete removal. Flexural three point bending and evaluation of
shear properties could lead to a better understanding as to the role of GAGs in
bioprosthetic heart valves.
Neomycin, a natural hyaluronidase inhibitor, did not completely inhibit
degradation of GAGs in pericardial tissue. Hyaluronic acid accounts for only 6% of the
total GAGs in the tissue. The mechanism by which GAGs are maintained may be
because of the NEO amine functionalities and its ability to bind the remaining carboxyl
groups of the GAGs to collagen. Further studies could include evaluation an alternative
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to NEO which will have similar amine functionalities for binding carboxyl groups on
GAGs, to determine if NEO is an enzyme inhibitor in pericardial tissue.
NEO showed the ability to stabilize GAGs after storage and against enzyme, but
once implanted valves will be subjected to a variety of mechanical stresses such as shear,
tension, compression. Accelerated fatigue testing is the next logical investigation to
determine if the durability of pericardial bioprosthetic heart valves is improved by the
stabilization of GAGs.
Prevention of calcification was not achieved with the addition of NEO to
traditional Glut treatment.

Future studies should combine NEO fixation with anti-

calcification treatments such as ethanol incubation for prevention of calcification.
Studies could also evaluate the effects of GAG stabilization on the tissue without the use
of Glut which is known to cause calcification.
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